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Edited by Hans-Dieter KlenkAbstract Sendai virus C protein interacts with the signal
transducer and activator of transcription (STAT) 1. This
interaction is believed to be essential for the Sendai virus
inhibition of the interferon (IFN) response. We here analyzed
CF170S (a C protein mutant with the F170S mutation) with no
STAT1-binding ability. CF170S lacked the ability to inhibit the
IFN-a response, but retained the ability to inhibit the IFN-c
response. IFN-c stimulation caused STAT1 phosphorylation,
formation of the gamma-activated factor capable of binding to a
gamma-activated sequence DNA probe, and STAT1 nuclear
translocation, even in the presence of CF170S. These results
suggest that C protein has the STAT1-binding-independent anti-
IFN-c mechanism, which targets processes after the STAT1
nuclear translocation event.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Interferons (IFNs) are cytokines, which play a pivotal role in
the host defense against virus infection. To antagonize the host
IFN system, viruses in the Paramyxovirinae have acquired the
ability to block IFN signaling during evolution [1–4]. Viral
proteins responsible for this anti-IFN function are accessory
proteins, V and/or C proteins encoded by the P gene. Most, if
not all, of the paramyxovirus IFN antagonists (V and/or C
proteins) interact with the signal transducer and activator of
transcription (STAT) 1, a key component common to both
IFN-a=b and IFN-c signaling pathways, and the STAT1-in-
teraction appears to be essential for their anti-IFN function.* Corresponding author. Fax: +81-776-61-8104.
E-mail address: bin@fmsrsa.fukui-med.ac.jp (B. Gotoh).
Abbreviations: CBP, CREB-binding protein; DMEM, Dulbecco’s
minimum essential medium; EMSA, electrophoretic mobility shift
assay; GAF, gamma-activated factor; GAS, gamma-activated se-
quence; GST, glutathione S-transferase; IFN, interferon; ISG, IFN-
stimulated gene; IRF, IFN regulatory factor; ISGF3, IFN-stimulated
gene factor 3; ISRE, IFN-stimulated response element; NTA, Ni–
nitrilotriacetic acid; ORF, open reading frame; SOV, sodium ortho-
vanadate; PAGE, polyacrylamide gel electrophoresis; pS, serine
phosphorylated; pY, tyrosine phosphorylated; SDS, sodium dodecyl
sulfate; SeV, Sendai virus; STAT, signal transducer and activator of
transcription
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doi:10.1016/j.febslet.2004.05.001For example, V protein of simian virus 5, mumps virus or
human parainﬂuenza virus type 2 interacts with host cellular
molecules including STAT1, thereby inhibiting IFN signaling
through proteasome-mediated degradation of STAT1 or
STAT2 [5–14]. On the contrary, interaction of Nipah virus or
Hendra virus V protein with STAT1 does not lead to STAT
degradation but results in the inhibition of the STAT nuclear
translocation, thereby blocking IFN signaling [15,16]. Simi-
larly, Sendai virus (SeV) C protein also interacts with STAT1
[17,18] and blocks IFN signaling [19,20], but the C-STAT1
interaction never results in STAT1 degradation in many cell
types including HeLa, HEC-1B, and U118 cell lines [6,17,19–
23] except for some cell types [18,24–26]. The aim of this study
is to better understand how SeV C protein inhibits the IFN
response without degrading STAT1.
IFN-a=b binds to type I IFN receptor, causing phosphory-
lation of STAT1 on Tyr701 and of STAT2 on Tyr690 following
activation of receptor-associated JAK kinases, JAK1 and
TYK2 [27]. The tyrosine phosphorylated (pY) STAT1 and pY-
STAT2 form a heterodimer, translocate into the nucleus, and
combine with IFN regulatory factor (IRF)-9 to form a het-
erotrimer complex termed IFN-stimulated gene factor 3
(ISGF3). On the other hand, binding of IFN-c to Type II IFN
receptor causes phosphorylation of STAT1 on Tyr701 follow-
ing activation of receptor-associated kinases, JAK1 and JAK2.
The pY-STAT1 forms a homodimer termed gamma-activated
factor (GAF) and translocates into the nucleus. The ISGF3 or
GAF then binds to IFN-stimulated response elements (ISREs)
or gamma-activated sequence (GAS) sites, respectively, in the
promoters of the IFN-stimulated genes (ISGs). Maximal
activation of the GAF-mediated transcription requires phos-
phorylation of STAT1 on Ser727 besides Tyr701 [28]. The
phosphorylated STAT1 is eventually inactivated through
dephosphorylation by nuclear phosphatases, such as TC45
(the nuclear isoform of the ubiquitously expressed T-cell pro-
tein tyrosine phosphatase) [29] or SHP-2 (SH2 domain-con-
taining protein tyrosine phosphatase 2) [30], rapidly relocated
back to the cytoplasm and takes part in subsequent activation–
inactivation cycle [31–33].
SeV C protein is encoded by the C open reading frame (ORF)
that overlaps the P ORF in +1 frame on the P gene transcripts
[34]. The SeV CORF produces a nested set of C
0
, C, Y1 and Y2,
which are collectively referred to as C protein [35]. Translation
of C
0
, C, Y1 and Y2 initiates at diﬀerent positions, 81ACG,
114AUG, 183AUG, and 201AUG, respectively, but terminates at
the identical position, 726UAA. To elucidate signiﬁcance of the
C-STAT1 interaction for the inhibition of the IFN response, weblished by Elsevier B.V. All rights reserved.
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CF170S [19,36–38], which has a single amino acid substitution of
F to S at position 170 (F170S mutation) on the STAT1-binding
domain [39]. Analysis of these mutants showed a good corre-
lation between the STAT1-binding ability and the ability to
inhibit the IFN-a response and further suggested that the
STAT1-interaction contributed to the inhibitory eﬀect on IFN-
a-stimulated phosphorylation of STAT1 and STAT2. This
analysis also demonstrated that the near-complete inhibition of
tyrosine phosphorylation of STAT2 was crucial for the block-
ade of IFN-a signaling [39]. For the inhibition of the IFN-c
response, it was found that the C-terminal half fragment of C
protein prevented the GAF from binding to a GASDNA probe
in vitro [40]. This result suggests that C protein prevents for-
mation of the GAF capable of binding to GAS sites though
interacting with STAT1. All these ﬁndings suggest importance
of the STAT1-C interaction for the SeV inhibition of the IFN
response.However, during analysis of theCmutant proteins, we
unexpectedly found that CF170S, which has no STAT1-binding
ability, retained the ability to inhibit the IFN-c response.
In this article, we study on a molecular basis for the anti-
IFN-c mechanism of CF170S. The results suggest that SeV C
protein can inhibit the IFN-c response even without interact-
ing with STAT1 and this novel STAT1-interaction-indepen-
dent mechanism targets processes after the STAT1 nuclear
translocation event.2. Materials and methods
2.1. Cells
HeLa cells were maintained in Dulbecco’s minimum essential me-
dium (DMEM) supplemented with 10% fetal calf serum. HeLa-C
(H-C) and HeLa-CF170S (H-CF170S) cells were maintained in DMEM
supplemented with 10% fetal calf serum and 0.8 mg/ml geneticin
(G418) [39].
2.2. Reporter gene assay
Cells in a 96 well plate were transfected with 30 ng of either pGAS-
TA-Luc or pISRE-TA-Luc (Clontech), and 5 ng of pRL-TK-luc
(Clontech) together with 30 ng of pEFneo empty vector [41] (a gift
from H. Asao), pEFneo-C or pEFneo-CF170S [39] by using the Fu-
GENE 6 transfection reagent (Roche Molecular Biochemicals). At
20 h post-transfection, the cells were mock-treated or treated with
either human recombinant IFN-c (500 IU/ml) (R&D Systems Inc.,
Minneapolis, MN) or IFN-a-2a (1000 IU/ml; Takeda Chemical In-
dustries, Osaka, Japan) for 6 h and measured for luciferase activities by
using a Dual-Glo Luciferase assay system (Promega) according to the
manufacturer’s protocol. Fireﬂy luciferase activity, expressed in rela-
tive light units, was normalized to Renilla luciferase activity.
2.3. Western blot analysis
Cells were lysed in an extraction buﬀer (10 mM HEPES, pH 7.9,
300 mM NaCl, 0.25% NP-40, 10% glycerol, 1 mM EDTA, 1 mM
EGTA, 1 mM sodium orthovanadate (SOV; Na3VO4), and 1 mM
DTT) containing a protease inhibitor cocktail (Sigma) [17] unless
otherwise mentioned. Western blot analysis was performed, as
described previously [17], with an anti-pY-STAT1 (No. 9171), (Cell
Signaling Technology, Beverly, MA), anti-serine phosphorylated (pS)-
STAT1 (No. 06-802) (Upstate Biotechnology, NY), anti-STAT1 (sc-
346 or sc-464), anti-IRF-1 (sc-497) (Santa Cruz Biotechnology, CA) or
anti-RGS-His (No. 34610) (Qiagen) antibody.
2.4. Pull down assay with glutathione S-transferase fusion proteins
Glutathione S-transferase (GST), GST fusion C (GST-C) and GST
fusion CF170S (GST-CF170S) were puriﬁed from Escherichia coli as de-
scribed previously [39]. Extracts (150 lg) from HeLa cells treated
with IFN-c (500 IU/ml) for 1 h were mixed with 10 ll of 50% slurry ofGST, GST-C or GST-CF170S (2–4 lg) conjugated glutathione–Sepha-
rose beads (Amersham Pharmacia Biotech) and incubated for 1 h at
4 C with gentle rotation. The beads were then washed four times with
the extraction buﬀer. Proteins bound to the beads were eluted by
adding sodium dodecyl sulfate (SDS)-gel loading buﬀer and separated
by SDS–7.5% polyacrylamide gel electrophoresis (PAGE).
2.5. Pull down assay with Ni–nitrilotriacetic acid beads
Cells were lysed in a lysis buﬀer (50 mM NaH2PO4, 300 mM NaCl,
0.25% NP-40, and 5 mM 2-mercaptoethanol) containing the protease
inhibitor cocktail. The lysates clariﬁed by centrifugation (250 lg) were
incubated with Ni–nitrilotriacetic acid (NTA) beads (Qiagen) at 4 C
for 1–2 h. The beads were then washed four times with the lysis buﬀer
containing 20 mM imidazole. Proteins bound to the beads were eluted
by adding SDS-gel loading buﬀer and separated by SDS–7.5%PAGE.
2.6. Electrophoretic mobility shift assay
Electrophoretic mobility shift assay (EMSA) was performed with a
32P-labeled synthetic DNA probe derived from GAS of the human
IRF-1 gene [42] as previously described [17,40].3. Results
3.1. The F170S mutation does not abolish the anti-IFN-c ability
of C protein
We previously showed that SeV C protein interacted with
STAT1 through its C-terminal half domain (aa 85–204) [40].
The F170S mutation on this C-terminal region abolished not
only the STAT1-binding ability but also the ability to inhibit
the IFN-a response [18,24,39]. This ﬁnding suggests impor-
tance of the C-STAT1 interaction for the inhibition of the
IFN-a response. To clarify its signiﬁcance for the inhibition of
the IFN-c response, we compared the eﬀect of CF170S and
original C on activation of the IFN-c-responsive reporter gene.
HeLa cells were transfected with either empty vector (pEF-
neo), C-expression vector (pEFneo-C), or CF170S-expression
vector (pEFneo-CF170S) together with an IFN-c-responsive
reporter plasmid (pGAS-TA-Luc) and the induction of lucif-
erase activity was assayed after IFN-c treatment. Contrary to
our expectation, activation of the IFN-c-responsive promoter
was signiﬁcantly suppressed by CF170S, as well as C, although
the suppression by CF170S was slightly weaker (Fig. 1A). This
result conﬂicted with the previous data presented by Garcin
et al. [24]. To conﬁrm the anti-IFN-c ability of CF170S, we next
examined the eﬀect of CF170S on the IFN-c-mediated induction
of ISG products such as IRF-1 and STAT1 by using previ-
ously established H-C and H-CF170S, which are HeLa cell lines
that stably express RGSH6 epitope tagged C and C
F170S, re-
spectively [39]. The expression levels of C and CF170S were al-
most the same (Fig. 1B). Levels of IRF-1 and STAT1 in each
cell line before and after IFN-c treatment were estimated by
Western blot analysis (Fig. 1C). Consistent with the result of
the reporter gene experiment, induction of STAT1 and IRF-1
was signiﬁcantly suppressed in both H-C and H-CF170S, al-
though CF170S again appeared to be slightly inferior in sup-
pression. Taken together, these results demonstrate that CF170S
retains the anti-IFN-c ability almost comparable to that of C.
This unexpected ﬁnding urged us to reexamine the eﬀect of
CF170S on the IFN-a response. As shown in Fig. 1D, response
of H-CF170S to IFN-a was closer to that of the control HeLa
rather than that of H-C. In addition, notable elevation of the
STAT1 level was observed in H-CF170S after IFN-a treatment
(Fig. 1E). These results conﬁrm the previous conclusion that
CF170S lacks most of the anti-IFN-a ability [39].
Fig. 2. Eﬀect of C and CF170S on IFN-c-stimulated phosphorylation of
STAT1. HeLa, H-C, or H-CF170S cells were treated with IFN-c (500
IU/ml) and then harvested at the indicated time points. Proteins in the
cell extracts were separated by SDS–7%PAGE for Western blot
analysis with an anti-pY-STAT1 antibody, anti-pS-STAT1 antibody
and anti-STAT1 (sc-346) antibody.
Fig. 1. Eﬀect of C and CF170S on the IFN response. Panels A and D:
HeLa cells were transfected with empty pEFneo vector (vec),
pEFneo-C or pEFneo-CF170S together with pRL-TK-luc and either
pGAS-TA-Luc (Panel A) or pISRE-TA-Luc (Panel D). Cells were then
mock-treated or treated with IFN-c (500 IU/ml) (Panel A) or IFN-a
(1000 IU/ml) (Panel D) for 6 h. Luciferase activity was measured as
described in Section 2. Data represent the mean values of the nor-
malized luciferase activities from quadruplicate samples. Panel B: The
extracts from HeLa, H-C or H-CF170S cells were subjected to SDS–
12.5%PAGE for Western blot analysis with an anti-RGS His antibody.
Panels C and E: HeLa, H-C, and H-CF170S cells were mock-treated (–)
or treated with IFN-c (500 IU/ml) (Panel C) or IFN-a (1000 IU/ml)
(Panel E) for 16 h. Proteins in the cell extracts were separated by XV
Pantera system (SDS-7.5%-Perfect NT Gel) (DRC, Tokyo, Japan) for
Western blot analysis with an anti-IRF-1 or anti-STAT1 (sc-464) an-
tibody. Results are representatives of three independent experiments.
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STAT1
Discovery of the anti-IFN-c activity of CF170S raised an es-
sential question of how CF170S inhibited the IFN-c response
without interacting with STAT1. We ﬁrst examined the eﬀect
on IFN-c-stimulated phosphorylation of STAT1. HeLa, H-C,
and H-CF170S cells were treated with IFN-c for various periods
and the levels of pY-STAT1, pS-STAT1 and STAT1 were
estimated by Western blot analysis (Fig. 2). The level of pY-
STAT1 in the control HeLa cells reached a maximum at 2–4 h
of IFN-c stimulation and then gradually declined thereafter. In
contrast, in H-C and H-CF170S, pY-STAT1 continued to
accumulate and persisted at higher levels for at least 24 h of
IFN-c stimulation (Fig. 2). The reason why pY-STAT1 ac-
cumulated in the presence of C or CF170S will be discussed
later. In all cell lines, STAT1 was serine-phosphorylated in
response to IFN-c stimulation, although the levels of pS-
STAT1 in H-C on the whole appeared to be slightly lower
(Fig. 2). These results indicate that neither C nor CF170S in-
hibits IFN-c stimulated phosphorylation of STAT1 on both
Tyr701 and Ser727.
3.3. Does CF170S speciﬁcally bind to pY-STAT1?
Garcin et al. [26] have recently shown that CF170S does not
bind to unphosphorylated STAT1 but binds to pY-STAT1,and emphasized importance of the N-terminal region present
only in the larger forms, C
0
and C, for the C-pY-STAT1
interaction. If this is the case, it is possible that this speciﬁc
interaction between CF170S and pY-STAT1 may be involved in
the inhibition of the IFN-c response. However, we had pre-
viously obtained conﬂicting data [39]. The pull down assay of
IFN-a-treated cell extracts with GST-CF170S had showed that
CF170S did not bind to either unphosphorylated STAT1 or pY-
STAT1. Nevertheless, this experiment does not completely
exclude the possibility that CF170S may interact with pY-
STAT1 generated by IFN-c stimulation, because pY-STAT1
in the IFN-c-treated cell extract is present predominantly as a
homodimer, whereas it is present as the heterotrimer ISGF3 or
STAT1–STAT2 heterodimer in the IFN-a-treated cell extract.
Thus, we performed a pull down assay using IFN-c-treated
HeLa cell extracts. As shown in Fig. 3A, both STAT1 and pY-
STAT1 bound to GST-C, whereas neither of them bound to
GST-CF170S. Similar results were obtained under the condi-
tions where sodium salt concentration in the binding and
washing buﬀers was reduced from 300 to 100 mM (data not
shown).
GST fusion proteins puriﬁed from E. coli may be diﬀerent,
in conformation, from native C synthesized in mammalian
cells. Thus, we also conducted a pull down assay using Ni–
NTA beads and extracts from H-C and H-CF170S that express
native RGSH6 epitope tagged C and C
F170S, respectively. Both
STAT1 and pY-STAT1 were pulled down again from H-C cell
extracts, whereas neither of them was pulled down from H-
CF170S cell extracts (Fig. 3B and C). These results ensure no
speciﬁc interaction of CF170S with STAT1.
3.4. CF170S does not inhibit either the GAF formation or STAT1
nuclear translocation
We next examined the eﬀect of CF170S on the downstream
IFN-c signaling of the STAT1 phosphorylation event. After
the phosphorylation event, pY-STAT1 forms a homodimer,
termed GAF, capable of binding to a GAS site. EMSA with a
Fig. 4. CF170S does not inhibit either formation of the GAF or the
STAT1 nuclear translocation. Panel A: HeLa, H-C or H-CF170S cells
were treated with IFN-c (500 IU/ml) for 1 h. The cell extracts were
subjected to EMSA with a 32P-labeled GAS probe. Panel B: HeLa, H-
C, or H-CF170S cells were mock-treated (–) or treated with IFN-c (1000
IU/ml) for 3 h and then ﬁxed. Cells were stained by the immunoﬂuo-
rescent staining method with an anti-pY-STAT1 antibody according to
the manufacturer’s protocol (Cell Signaling Technology, Beverly,
MA).
Fig. 3. CF170S does not bind to either unphosphorylated STAT1 or pY-
STAT1. Panel A: IFN-c-treated HeLa cell extracts were incubated
with GST, GST-C, or GST-CF170S immobilized on glutathione–
Sepharose beads for 1 h. The mixtures were then divided by centrifu-
gation into supernatant (sup) and pellet (pt) fractions. Proteins in each
fraction were separated by SDS–7.5%PAGE for Western blot analysis
with an anti-STAT1 (sc-464) or anti-pY-STAT1 antibody. Panel B:
Extracts (ex) from HeLa, H-C or H-CF170S cells were subjected to pull
down assay with Ni–NTA beads. Ni–NTA beads were collected by
centrifugation as a pellet (pt) fraction. Panel C: The extracts from
HeLa, H-C, or H-CF170S cells treated with IFN-c (500 IU/ml) for 1 h
were subjected to pull down assay as in Panel B. Proteins were sepa-
rated by the XV Pantera system for Western blot analysis with an anti-
STAT1 (sc-464) (Panel B) or anti-pY-STAT1 antibody (Panel C).
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disappearance of the GAF band in the presence of C (Fig. 4A)
[17,40]. In contrast, GAF complex was formed in the presence
of CF170S, which could bind to the GAS DNA probe (Fig. 4A).
Upon IFN-c stimulation, the GAF translocates into the nu-
cleus. Immunoﬂuorescent staining with an anti-pY-STAT1
antibody showed nuclear translocation of pY-STAT1 gener-
ated in response to IFN-c stimulation even in the presence of C
or CF170S (Fig. 4B). Taken together, these results indicate that
CF170S targets processes after the STAT1 nuclear translocation
event for the inhibition of the IFN-c response.
3.5. CF170S retains the ability to inhibit the STAT1
dephosphorylation event
To identify a target molecule of CF170S for the inhibition of
the IFN-c response, proteins binding to RGSH6 epitope tag-
ged CF170S or C were pulled down with Ni–NTA beads from
large amounts of H-CF170S or H-C cell extracts, and separated
by SDS-gradient PAGE followed by silver-staining. Unfortu-
nately, we failed to detect any speciﬁc band common to both
H-C and H-CF170S extracts.
Instead, we took notice of the aberrant accumulation of
pY-STAT1 in response to IFN-c stimulation as a common
feature of C and CF170S (Fig. 2). Since the overall level of
pY-STAT1 is determined by balance of phosphorylation and
dephosphorylation events, prolonged phosphorylation of
STAT1 may result from either an increase in JAK kinase
activity or a decrease in phosphatase activity. Indeed, theaccumulation of pY-STAT1 in the presence of C had been
previously found to be due to the inhibition of the pY-
STAT1 dephosphorylation event [23]. We thus determined
whether CF170S retained this ability. To monitor the rate of
STAT1 dephosphorylation, we used staurosporine, a kinase
inhibitor that blocks the continuous phosphorylation of
STAT1 by JAKs. After treatment with IFN-c for 1 h, media
were replaced with fresh media containing staurosporine
(Fig. 5A). In HeLa cells, the pY-STAT1 level rapidly de-
creased to near a basal level within 1 h after addition
of staurosporine. In contrast, the pY-STAT1 level in H-C or
H-CF170S maintained even 1 h after treatment with stauro-
sporine. It should be noted that the levels of pY-STAT1 in
H-C or H-CF170S in the absence of staurosporine were higher
than those in control HeLa. When HeLa cells were pre-in-
cubated with a phosphatase inhibitor, SOV, and then treated
with IFN-c for 1 h in the presence of SOV, the pY-STAT1
level in control HeLa was enhanced, whereas no enhance-
ment was observed in H-C or H-CF170S (Fig. 5B). Taken
together, these results indicate that both C and CF170S have
the common ability to inhibit STAT1 dephosphorylation.
Table 1







C + + +
CF170S ) + +
Y1a + + +
Y2a + + +
D1a + + +
D2a ) ) )
D3a ) ) )
C (aa 1–204), Y1 (aa 24–204), Y2 (aa 30–204), D1 (aa 85–204), D2 (aa
127–204), D3 (aa 30–126).
aResults from [39,40].
Fig. 5. CF170S retains the ability to inhibit STAT1 dephosphorylation.
Panel A: HeLa, H-C or H-CF170S cells were stimulated with IFN-c (500
IU/ml) for indicated time periods with or without addition of 100 nM
staurosporine (stauro) (Wako Pure Chemical Industries, Ltd., Osaka,
Japan) after 1 h of IFN-c treatment. Levels of pY-STAT1 and STAT1
were determined by Western blot analysis with an anti-pY-STAT1 or
anti-STAT1 (sc-346) antibody. Panel B: HeLa, H-C or H-CF170S cells
were treated with IFN-c (500 IU/ml) for indicated time periods with or
without addition of 1 mM SOV before 1.5 h of the IFN-c treatment.
Extracts were analyzed as in Panel A. Arrowheads indicate positions of
pY-STAT1 detected by anti-STAT1 antibody.
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In this article, we show that C protein can inhibit the IFN-c
response without interacting with STAT1. The F170S muta-
tion on the STAT1-binding domain abolishes the STAT1-
binding ability of C protein [18,39]. The abrogation of the
STAT1-binding ability, however, does not abolish the ability
to inhibit the IFN-c response (Fig. 1). Regarding the STAT1-
binding ability of CF170S, Garcin et al. [26] presented conﬂict-
ing data indicating the binding ability of CF170S for pY-STAT1
but not unphosphorylated STAT1. They further claimed that
the C-pY-STAT1 interaction required an N-terminal region
spanning amino acids 10–15 within the longer form of C
protein (C/C
0
). To determine whether CF170S could bind to pY-
STAT1, we conducted several experiments. The pull down
assay with GST-CF170S synthesized in E. coli or with RGSH6
epitope tagged CF170S synthesized in HeLa cells showed that
STAT1 did not bind to CF170S irrespective of its phosphory-
lation status (Fig. 3). The EMSA showed no shift of the GAF
band in the presence of CF170S (Fig. 4A), supporting the notion
that there are no molecules interacting with the GAF. Fur-
thermore, our previous study revealed that the N-terminallytruncated C fragments – Y1 (aa 24–204), Y2 (aa 30–204) and
D1 (aa 85–204) – retained the ability to bind to both un-
phosphorylated and phosphorylated STAT1 molecules [39,40].
This indicates that the N-terminal region (aa 10–15) of C
protein is not essential for the C-STAT1 interaction. On the
contrary, the STAT1 domain responsible for interacting with
the D1 domain was found to be located at its N-terminal re-
gion but not its C-terminal region containing the phosphory-
lation site of Tyr701 [40]. All these results are consistent with
the inability of CF170S to bind to STAT1. At present, we cannot
provide any reasonable explanations for the discrepancies be-
tween their and our results. The possibility cannot be ruled out
that the diﬀerence in the cell type and/or SeV strain analyzed
might aﬀect the results.
The analysis of IFN-c signaling in the presence of CF170S
(Figs. 2 and 4) demonstrates that CF170S does not inhibit either
STAT1 phosphorylation, formation of the GAF, or STAT1
nuclear translocation. Thus, the novel anti-IFN-c mechanism,
independent of the STAT1-binding, targets a process after the
STAT1 nuclear translocation event; probably the GAF-medi-
ated transcriptional process itself. It is likely that CF170S in-
teracts with an unknown cellular molecule that participates in
and plays a crucial role in the GAF-mediated transcriptional
process. Through interacting with that target molecule, CF170S
may prevent the GAF from binding to GAS sites in the
chromosomal DNA or may inhibit the subsequent process.
One of such candidates is CREB-binding protein (CBP)/p300,
a cofactor that regulates the transactivation function of the
GAF [43]. Co-precipitation experiments, however, failed to
detect interaction between CBP/p300 and C (unpublished
data). Human parainﬂuenza virus type 3 closely related to SeV
also inhibits the IFN-c response, but does not inhibit forma-
tion of the GAF complex [6]. No shift of the GAF band was
observed [6]. These results might be explainable, given that the
target molecule of human parainﬂuenza virus type 3 would be
identical to that of SeV CF170S.
To ﬁnd a clue about how CF170S would inhibit the GAF-
mediated transcription, we took notice of a common feature of
C and CF170S; the accumulation of pY-STAT1 in response to
IFN-c stimulation (Fig. 2). The accumulation was found to be
at least in part due to the inhibition of the STAT1 dephos-
phorylation event (Fig. 5). Table 1 summarizes features of
mutant C proteins, including truncated C proteins previously
characterized, Y1, Y2, D1, D2 (aa 127–204), and D3 (aa 30–
126) [39]. There is a good correlation between the ability to
inhibit the IFN-c response and the ability to cause the pY-
STAT1 accumulation. Accordingly, the inhibition of the
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STAT1-binding-independent anti-IFN-c mechanism. It is
unclear, at present, whether the inhibition of the STAT1 de-
phosphorylation is essential for the inhibition of the STAT1-
binding-independent mechanism, or only an epiphenomenon.
Previous studies showed that the C-terminal half fragment of
C protein had the ability to prevent the GAF from binding to a
GAS element in vitro. This ﬁnding suggests that C protein
blocks IFN-c signaling by inhibiting formation of the GAF
capable of binding to the GAS probe through the STAT1 in-
teraction. C protein thus appears to inhibit the IFN-c response
at twodiﬀerent phases; the formation of theGAS-binding-active
GAF (STAT1-binding-dependent phase) and the subsequent
process after the STAT1nuclear translocation (STAT1-binding-
independent phase). The inferiority of CF170S to C in the IFN-c
ability (Fig. 1A and C) suggests signiﬁcance of the STAT1-
binding dependent phase for the anti-IFN-c ability.However, to
precisely assess its signiﬁcance, isolation of C protein mutants
will be needed, which retain the STAT1-binding ability but lose
the latter STAT1-binding-independent mechanism.
As shown in Fig. 1D and E, CF170S has lost most of the anti-
IFN-a ability [39], but appears to still retain a slight inhibitory
eﬀect on the IFN-a response. This slight inhibition was re-
producibly observed. It is possible that this inhibition may also
result from the novel STAT1-binding-independent mechanism.
Finally, the possibility should be kept in mind, although un-
likely, that CF170S might have acquired the STAT1-binding-
independent mechanism, which original C might not have.
Which molecule is a target of the STAT1-binding-indepen-
dent mechanism? Identiﬁcation of the target would be im-
portant for full understanding of not only the SeV strategy for
evading the IFN response but also mechanism of the GAF-
mediated transcription.
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